Wangqing Chen
Overview
Explore the profile of Wangqing Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang Z, Jiang R, Wang Y, Chen W, Chen X, Yin M
Clin Transl Med
. 2025 Mar;
15(3):e70256.
PMID: 40038877
Introduction: Tyrosine kinase 2 (TYK2)-dependent cytokine signalling is integral to the pathogenesis of psoriasis. While BMS-986165, a highly selective TYK2 inhibitor, has recently been approved for oral treatment of psoriasis,...
2.
Li R, Zhou X, Mao M, Chen W, Zhu W, Chen X
Arch Dermatol Res
. 2025 Feb;
317(1):410.
PMID: 39951122
Dihydromyricetin (DMY), a flavonoid, belongs to a class of natural compounds and possesses anti-inflammatory properties. The objective of this research is to investigate the effects and mechanism of DMY in...
3.
Mao M, Yuan Y, Li R, Kuang Y, Lu Y, Zhu W, et al.
Int Immunopharmacol
. 2025 Feb;
149:114196.
PMID: 39904035
Methotrexate (MTX) is a widely used medication that can also be employed in the treatment of psoriasis. Previous studies have emphasized that MTX can induce dysbiosis of the gut microbiota,...
4.
Zhang Y, Zang C, Mao M, Zhang M, Tang Z, Chen W, et al.
Autoimmun Rev
. 2025 Jan;
24(4):103753.
PMID: 39842534
Autoimmune diseases (ADs) are a group of complex, chronic conditions characterized by disturbance of immune tolerance, with examples including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and psoriasis. These diseases...
5.
Zang C, Li J, Zhang Y, Deng W, Mao M, Zhu W, et al.
Exp Dermatol
. 2024 Sep;
33(9):e15157.
PMID: 39227185
Clinical research has revealed that inflammatory skin diseases are associated with dyslipidaemia. Modulating lipids is also a rising potential treatment option. However, there is heterogeneity in the existing evidence and...
6.
Jin L, Dong L, Pei S, Chen X, Kuang Y, Chen W, et al.
Eur J Pharmacol
. 2024 Feb;
968:176382.
PMID: 38311277
Psoriasis is a chronic, recurrent, inflammatory dermatosis accompanied by excessive activation of dendritic cells (DCs), which are primarily responsible for initiating an immune response. The bromodomain and extraterminal domain (BET)...
7.
Zhao S, Wu L, Kuang Y, Su J, Luo Z, Wang Y, et al.
Int J Oncol
. 2023 Nov;
64(1).
PMID: 37997849
Subsequently to the publication of the above article, an interested reader drew to the authors' attention that the β‑actin bands shown for the western blots portrayed in Fig. 4A and...
8.
Mao M, Dian Y, Sun Y, Chen W, Zhu W, Deng G
Front Cell Infect Microbiol
. 2023 Nov;
13:1237277.
PMID: 37920449
Background: Azvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of...
9.
Zang C, Liu J, Mao M, Zhu W, Chen W, Wei B
Dermatol Ther (Heidelb)
. 2023 Aug;
13(10):2331-2343.
PMID: 37653234
Introduction: Previous studies have proposed a possible gut-skin axis, and linked gut microbiota to psoriasis risks. However, there is heterogeneity in existing evidence. Observational research is prone to bias, and...
10.
Lai S, Xu L, Zhang L, Peng L, Li Y, Liu Y, et al.
Front Pharmacol
. 2023 Apr;
14:1141075.
PMID: 37033602
Inhibitors of programmed cell death protein 1 and its associated ligand (PD-L1) are widely used in cancer treatment. However, medical costs and benefits of PD-1/PD-L1 inhibitors need attention owing to...